Title : Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer.

Pub. Date : 2011 Oct

PMID : 21729667






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 We performed this trial to evaluate the efficacy and safety of saracatinib monotherapy in patients with estrogen receptor (ER)(-) and progesterone receptor (PR)(-) metastatic breast cancer (MBC). saracatinib progesterone receptor Homo sapiens